Press Releases from ViaCyte

Date
News
04.24.17

ViaCyte to Present at ARM’s 5th Annual Cell & Gene Therapy Investor Day in Boston

ViaCyte to also present at World Advanced Therapies and Regenerative Medicine Congress in London SAN DIEGO, April 24, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, today announced two presentations on April 27 at […]
03.29.17

ViaCyte and W. L. Gore & Associates Announce Collaborative Research Agreement to Develop Novel Implantable Delivery Technologies for Cell Therapies

SAN DIEGO, California and NEWARK, Delaware, March 29, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, and W. L. Gore & Associates, Inc. (“Gore”), a global materials science company, today announced a collaborative research […]
02.23.17

Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapies for Type 1 Diabetes

  SAN DIEGO and SAN FRANCISCO, February 23, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, and Beyond Type 1, a not-for-profit advocacy and education group for those living with type 1 diabetes, today […]
02.21.17

ViaCyte to Present at Four Upcoming Healthcare Events

SAN DIEGO, February 21, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, today announced four presentations at upcoming healthcare events.  ViaCyte is advancing two novel cell replacement therapies as long-term diabetes treatments.  ViaCyte’s product […]
01.04.17

Twenty-two New Patents Are Added To ViaCyte’s Intellectual Property Portfolio

President and CEO, Paul Laikind, PhD to present at 2017 Biotech Showcase SAN DIEGO, January 4, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, today announced the addition of twenty-two new patents in 2016.  […]
Date
News
11.04.16

ViaCyte to Present at Healthcare Events in November

SAN DIEGO, November 4, 2016 – ViaCyte, Inc., a privately-held regenerative medicine company, today announced two presentations at upcoming healthcare events.  ViaCyte is advancing two novel cell replacement therapies as potential long-term type 1 diabetes […]
10.11.16

ViaCyte to Present at Healthcare Events in October

SAN DIEGO, October 11, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced four presentations at […]
10.04.16

ViaCyte to Provide a Corporate Update at 2016 Cell and Gene Meeting on the Mesa

SAN DIEGO, October 4, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of type 1 diabetes in clinical-stage development, today announced a […]
09.09.16

ViaCyte to Speak on Diabetes Panel at BioPharm America 2016

SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced participation on a […]
08.12.16

ViaCyte to Present at Rejuvenation Biology 2016

SAN DIEGO, August 12, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced a presentation at […]
07.21.16

ViaCyte Awarded New CIRM Grant to Develop PEC-Direct for High-Risk Type 1 Diabetes

SAN DIEGO, July 21, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company, today announced that the California Institute for Regenerative Medicine (CIRM) approved a grant of $3.9 million to support pre-clinical development of ViaCyte’s […]
06.22.16

ViaCyte to Present at ISSCR 2016 Annual Meeting

SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced two presentations at […]
04.20.16

ViaCyte to Present at Healthcare Events in April and May

SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced four presentations at […]
03.14.16

ViaCyte to Present at Upcoming Healthcare Events

SAN DIEGO, March 14, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at […]
03.01.16

ViaCyte to Present at JDRF TypeOneNation Summit Meetings in Washington DC and Los Angeles

SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced presentations at the […]
02.17.16

ViaCyte to Present at Upcoming Healthcare Events

ViaCyte to Present at Upcoming Healthcare Events SAN DIEGO, February 17, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in […]
02.03.16

ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell-Derived Approaches to Type 1 Diabetes

ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell-Derived Approaches to Type 1 Diabetes Preliminary data of STEP ONE clinical trial are promising SAN DIEGO, February 4, 2016 — ViaCyte, […]
01.06.16

ViaCyte to Present at Biotech Showcase 2016 in San Francisco

SAN DIEGO, January 6, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced a company presentation […]
Date
News
11.17.15

ViaCyte to Present at IDF World Diabetes Congress 2015

SAN DIEGO, November 17, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced a company presentation […]
11.16.15

ViaCyte Licenses Cell Differentiation Technology to Takara Bio Inc.

SAN DIEGO, November 16, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced that the Company […]
10.15.15

ViaCyte to Present at 14th Annual BIO Investor Forum

SAN DIEGO, October 15, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced a company presentation […]
09.24.15

ViaCyte to Present at Upcoming Healthcare Events

SAN DIEGO, September 24, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at […]
09.10.15

ViaCyte Announces the Publication of a Report on Macroencapsulated Stem Cell-Derived Insulin-Producing Cells and the Issuance of Three Patents

Published Study Shows Similar In Vivo Time-to-Function Between In Vitro-Produced Beta-like Cells and Pancreatic Progenitor Cells Designed to Mature Into Beta Cells In Vivo. SAN DIEGO, September 10, 2015 – ViaCyte, Inc., a privately-held regenerative […]
07.29.15

ViaCyte Announces Second Clinical Trial Site at University of Alberta

Dr. James Shapiro, who led the team that developed the “Edmonton Protocol,” will be lead investigator at the Canadian site SAN DIEGO, July 29, 2015 – ViaCyte, Inc., a privately-held regenerative medicine company with the […]
06.16.15

ViaCyte to Present Plenary Lecture at ISSCR 2015 Annual Meeting

SAN DIEGO, June 16, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a company presentation […]
05.14.15

ViaCyte to Present at London Regenerative Medicine Network and The World Stem Cells and Regenerative Medicine Congress 2015

SAN DIEGO, May 14, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced presentations at two upcoming […]
05.11.15

ViaCyte to Present at Cavendish Global Health Impact Forum

SAN DIEGO, May 11, 2015 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced two presentations at […]
04.23.15

ViaCyte to Present at GTCbio 2015 Diabetes Summit

SAN DIEGO, April 23, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced two presentations at […]
03.17.15

ViaCyte to Present at ARM’s Third Annual Regen Med Investor Day

SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. […]
03.03.15

ViaCyte to Present at JDRF TypeOneNation Research Summit

SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a […]
02.26.15

ViaCyte to Present at 35th Annual Cowen and Company Health Care Conference

SAN DIEGO, February 26, 2014 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced that Dr. Paul Laikind, […]
02.23.15

ViaCyte to Present at Two San Diego Events: Biocom’s Global Life Science Partnering Conference and UCSD Diabetes Public Forum

­ SAN DIEGO, February 23, 2014 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced two presentations by […]
01.12.15

JDRF Honors Current and Former ViaCyte Team with Top Scientific Excellence Award

San Diego, New York, and Los Angeles, January 12, 2015 — ViaCyte and JDRF announced today that the current and former ViaCyte team are being recognized by JDRF for their pioneering work in developing the […]
01.08.15

ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial

San Diego, January 8, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter […]
Date
News
12.22.14

ViaCyte to Present at Biotech Showcase in San Francisco

SAN DIEGO and SAN FRANCISCO, December 22, 2014 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced that […]
12.18.14

Study Further Validates Cell Therapy Approach to Reverse Type 1 Diabetes

Induced immune tolerance may reduce the need for long-term immunosuppression San Diego, California, December 18, 2014 — ViaCyte, Inc. announced today a preclinical study published online in Cell Stem Cell that describes a novel approach […]
11.20.14

ViaCyte to Present at 26th Annual Piper Jaffray Healthcare Conference

San Diego, California, November 20, 2014 — ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, today announced that Dr. Paul Laikind, President and Chief […]
11.06.14

ViaCyte Receives U.S. Patent Claiming Alternative Methods to Manufacture Pancreatic Progenitor Cells In Vitro

San Diego, California, November 6, 2014 — ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, announced today it has been granted U.S. patent 8,859,286, […]
10.29.14

ViaCyte’s VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted into First Patient

SAN DIEGO, Oct. 29, 2014 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the first patient in its Phase 1/2 study was successfully implanted with VC-01™, its embryonic stem cell-derived islet […]
10.06.14

ViaCyte, Inc. to Present at Upcoming Stem Cell Meeting on the Mesa Conference

San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, called VC-01™, will give two presentations at the annual […]
09.10.14

ViaCyte, Inc. Awarded $16.6 Million Accelerated Development Pathway Grant from CIRM to Expand Clinical Development of its VC-01™ Diabetes Therapy Candidate

San Diego, California, September 10, 2014 — ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, called VC-01, announced today that it has been […]
08.21.14

ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC.

San Diego, California, August 21, 2014 — ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research & Development LLC (Janssen), one of the […]
08.19.14

ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of VC-01™ Candidate Cell Replacement Therapy for Type 1 Diabetes

Company Plans to Immediately Initiate Phase 1/2 Clinical Trial San Diego, California, August 19, 2014 — ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the U.S. Food and Drug Administration (“FDA”) has accepted […]
08.08.14

ViaCyte, Inc. Raises $5.4 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product VC-01™ for Insulin-Dependent Diabetes

San Diego, California, August 8, 2014 — ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, announced today that it has completed a private […]
07.17.14

ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes

San Diego, CA — July 17, 2014 – ViaCyte, Inc., a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, today announced that it has filed an Investigational New Drug […]
07.08.14

ViaCyte Achieves Significant Milestone with ISO 13485:2003 Certification for its Encaptra Drug Delivery System

San Diego, CA — July 8, 2014 — ViaCyte, Inc. (“ViaCyte”), a privately held regenerative medicine company developing a cell therapy for treatment of type I diabetes, today announced it has received International Standards Organization (ISO) […]
05.29.14

ViaCyte and Asterias Biotherapeutics Settle Patent Dispute

San Diego, CA, May 29, 2014 – ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with insulin-dependent diabetes, announced today that the Company has settled […]
02.06.14

JDRF to Provide Additional Support for Upcoming Clinical Trial of ViaCyte’s Encapsulated Cell Therapy for Type 1 Diabetes

[one_half last=”no”][/one_half][one_half last=”yes”][/one_half] — Potentially transformative therapy for individuals with type 1 diabetes nearing major milestone — New York, NY and San Diego, CA, February 6 2014 – JDRF, the world’s largest non-profit supporter of […]
Date
News
12.19.13

ViaCyte Appoints Mark Foletta, former CFO of Amylin, to its Board of Directors

SAN DIEGO, Dec. 19, 2013 — ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors. Mr. Foletta is a seasoned financial executive […]
12.02.13

ViaCyte to Present at the 25th Piper Jaffray Healthcare Conference

San Diego, California, December 2, 2013 — ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today announced it will present at the 2013 Piper Jaffray Healthcare […]
10.29.13

ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine

San Diego, California, October 29, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that […]
10.16.13

ViaCyte to Present at the JDRF 8th Annual T1D Global Path to a Cure Symposium

San Diego, California, October 16, 2013 — ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today announced that it will present a scientific overview at the […]
10.10.13

Viacyte to Present Update On VC-01™ Combination Product Development at 2013 Stem Cell Meeting on The Mesa

San Diego, California, October 10, 2013 – ViaCyte, Inc. announced today that an update on the Company’s progress toward a transformative stem cell-derived cell therapy for the treatment of type 1 diabetes will be presented […]
07.10.13

ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes

Provides match for $10.1M CIRM Strategic Partnership Award San Diego, California, July 10, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of […]
07.03.13

Viacyte Inc. selected as one of 2013’s “Cool Companies”

The San Diego Venture Group has announced its “Cool Companies” for the July 12 Venture Summit. The 30 San Diego businesses, which include Viacyte Inc., will be prominently featured at Venture Summit in front of 700 attendees, including […]
02.13.13

JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte

[one_third last=”no”][/one_third] [one_fourth last=”no”][/one_fourth] [one_third last=”yes”][/one_third] Treatment being developed would use encapsulation to protect new insulin-producing cells derived from a stem cell precursor New York, NY and San Francisco, CA, February 13, 2013 – JDRF, […]
01.31.13

ViaCyte’s Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

San Diego, California, January 31, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that […]
01.10.13

Next Steps in Potential Stem Cell Therapy for Diabetes

UC San Diego-based study, collaborating with scientists from San Diego-based biotech company ViaCyte, Inc., looks at differentiation of hESCs in endocrine cell progression
Date
News
10.29.12

ViaCyte Appoints Steve Altman to its Board of Directors

San Diego, California, October 29, 2012 – ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Steve R. Altman has been appointed to its Board […]
10.26.12

ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy

San Diego, California, October 26, 2012 – ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that it has received a $10.1 million Strategic Partnership Award […]
06.25.12

ViaCyte Appoints Dr. Paul Laikind Chief Executive Officer

SAN DIEGO, June 15, 2012 /PRNewswire/ — ViaCyte, Inc. today announced the appointment of seasoned entrepreneur, Paul Laikind, Ph.D., as President & Chief Executive Officer. Allan Robins, Ph.D., who was serving as Acting CEO, will […]
06.21.12

Scientists Outsmart the Immune System to Better Match People with Organs

Popular Science, June 21, 2012: Viacyte, a company based in San Diego, is one of several research groups working to make containers that can house cells. It’s testing a bioartificial pancreas to treat diabetes: a plastic […]
03.12.12

ViaCyte Licenses Technologies to Nestlé Institute of Health Sciences

Nestlé Institute of Health Sciences (NIHS, Lausanne, Switzerland), has licensed technology from ViaCyte, Inc., for basic research purposes SAN DIEGO, March 12, 2012.  The license agreement provides access to ViaCyte’s cell engineering technologies to support […]
02.07.12

Towards a Diabetes Cure: Beta Cell Updates from the PDRC Symposium

A Sweet Life, February 07, 2012: It was late January and the temperature was in the mid-seventies without a cloud in the sky – one reason to love being in San Diego. Another reason? The Pediatric Diabetes Research […]
01.09.12

What’s Up with Diabetes Stem Cell Research Firm ViaCyte

Diabetes Mine, January 9, 2012: We were familiar with the company ViaCyte through its former identity as NovoCell, when we reported that they’d managed to successfully control diabetes in mice using embryonic stem cells back […]
Date
News
12.06.11

Athens lab tackles diabetes

Athens Banner Herald/Online Athens, December 6, 2011: Athens researchers believe they’re close to human trials for a device that could use stem cells to control Type 1 diabetes. Research company Viacyte has labs in both San […]
11.30.11

Video: Stem Cell Meeting on the Mesa

Stem Cell Meeting on the Mesa, Salk Institute for Biological Studies, La Jolla, California CIRM Disease Team Reports, November 30, 2011: Dr. Robins received a B.S. with honors in biochemistry and a Ph.D. in molecular biology […]
11.09.11

Video: Diabetes: Advancing Stem Cell Therapies

2011 CIRM Grantee Meeting, Diabetes:  Advancing Stem Cell Therapies, November 9, 2011: Eugene Brandon speaks at the 2011 CIRM Grantee Meeting about Viacyte’s efforts to develop a stem cell based treatment for diabetes. CIRM has awarded Viacyte […]
11.07.11

Diabetes and the stem cell promise

Los Angeles Times, Eryn Brown, November 07, 2011: The search for a cure, or even a less-complicated treatment, is still on a long road to its goal. Ever since scientists started talking about the medical potential of embryonic […]
08.09.11

ViaCyte Announces Executive Management Changes

Allan Robins, Ph.D., Appointed Acting Chief Executive Officer Kevin D’Amour, Ph.D., Promoted to Chief Scientific Officer San Diego, CA (August 9, 2011) – ViaCyte, Inc. today announced changes to its executive management team, including the […]
06.15.11

ViaCyte Names Michael Scott VP, Device Research & Development

San Diego, CA (June15, 2011) – ViaCyte, Inc. today announced the appointment of Michael J. Scott, Ph.D. as Vice President, Device Research and Development, reporting to John West, President and Chief Executive Officer. In this […]
05.31.11

New Stem Cell Implant Holds Hope For Diabetics

KPBS San Diego, Peggy Pico, May 31, 2011: Think of the new device as a tea bag of sorts. Only this small bag is filled with cells derived from embryonic stem cells, that turn into […]
05.30.11

San Diego company studies stem cell implant as a Type 1 diabetes treatment

Los Angeles Times, Amber Dance, May 30, 2011: A pouch full of brand-new cells may one day reduce the need for people with Type 1 diabetes to take daily insulin shots. ViaCyte Inc. of San Diego has already […]
05.13.11

ViaCyte, Inc., Names Anthony Gringeri Chief Development Officer

San Diego, CA (May 13, 2011) – ViaCyte, Inc., a preclinical cell therapy company focused on diabetes, today announced the appointment of Anthony (“Tony”) Gringeri as Chief Development Officer. Dr. Gringeri brings to ViaCyte more […]
04.13.11

Cellular Dynamics Licenses Technology from ViaCyte

Licensing Agreement Allows CDI to Utilize ViaCyte’s Patented Technology for the Differentiation and Manufacture of iCell® Hepatocytes MADISON, Wis., Apr. 13, 2011 – Cellular Dynamics International (CDI), the world’s largest producer of tissue cells derived […]
01.26.11

Taxpayer funding for stem cell research generates 2,739 jobs annually

Union Tribune San Diego, Keith Darcé, January 26, 2011:  The $1.1 billion that California taxpayers have provided for stem cell research in the state is generating 2,739 jobs annually, according to a report being released today by […]
Date
News
06.28.10

Building a Substitute Pancreas for Diabetics

 MIT Technology Review, Emily Singer. June 28, 2010:  A startup hopes implanted insulin-producing cells will free diabetics from insulin injections. Implants containing specially wrapped insulin-producing cells derived from embryonic stem cells can regulate blood sugar in mice […]
05.05.10

ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes

San Diego, CA (May 5, 2010) – ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents: On April 13, the Company was […]
05.05.10

Novocell Becomes ViaCyte, Inc, as it Accelerates Pre-clinical Development of a Stem Cell Derived Treatment for Diabetes

San Diego, CA (May 5, 2010) – Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company’s shareholders and Board of Directors approved a name change to ViaCyte, Inc. […]
Date
News
10.28.09

Novocell is the Recipient of a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes

San Diego, CA (October 28, 2009) – Novocell, Inc., a preclinical stage diabetes company, today announced that it will receive a Disease Team award totaling $20 million from the California Institute for Regenerative Medicine (CIRM). […]
06.03.09

Novocell Obtains U.S. Patent for Drug Screening Human Embryonic Cell Derived-Endoderm Cells

Patent Covers Methods for Identifying Endoderm Differentiation Factors San Diego, CA (June 3, 2009) – Novocell, Inc., a stem cell engineering company, today announced that it has received U.S. Patent No. 7,541,185 with method claims […]
05.19.09

Novocell Awarded Patent for Innovative Stem Cell Therapy for Diabetes

Patent Covers Groundbreaking Process for the Generation of Insulin-producing Cells from Embryonic Stem Cells San Diego, CA (May 19, 2009) – Novocell, Inc., a stem cell engineering company, today announced that it has received U.S. […]
05.11.09

Novocell Names John West Chief Executive Officer

San Diego, CA (May 11, 2009) – Novocell, Inc., a stem cell engineering company, today announced the appointment of John West as President, Chief Executive Officer and a member of its Board of Directors. West, […]
05.06.09

Novocell Receives Grant Awards from California Institute for Regenerative Medicine for Stem Cell Therapy Development

San Diego, CA (May 6, 2009) – Novocell, Inc., a stem cell engineering company, today announced that it will receive two funding awards totaling $6.2 million from the California Institute for Regenerative Medicine (CIRM). The […]
03.30.09

Novocell Awarded Seminal Stem Cell Patent

San Diego, CA (March 31, 2009) – Novocell, Inc., a stem cell engineering company, today announced that it has received U.S. Patent 7,510,876 with claims covering human definitive endoderm cells, an essential cell for generating […]
03.02.09

Novocell honored by National Diabetes Organization

The San Diego Chapter of the Juvenile Diabetes Research Foundation (JDRF) will honor Novocell, Inc. at their 10th Anniversary Promise Ball on Saturday, May 16, 2009. The La Jolla based company is dedicated to developing […]
Date
News
12.19.08

Novocell Announces Non-Exclusive Drug Discovery Collaboration with Pfizer Research to Utilize Novocell’s Stem Cell-derived Pancreatic Progenitor Cells

San Diego, CA (December 19, 2008) – Novocell, Inc., a stem cell engineering company, today announced it has entered into a non-exclusive drug discovery collaboration with Pfizer giving Pfizer access to Novocell’s proprietary pancreatic progenitor […]
12.09.08

Novocell Announces Collaboration with World-Renowned Stem Cell Researcher Shinya Yamanaka of Kyoto University

Pioneers in Stem Cell Research to Explore Creation of Human Islet Cells from iPS Cells San Diego, CA (December 9, 2008) – Novocell, Inc., a stem cell engineering company, today announced a collaboration with renowned […]
11.25.08

Novocell CEO to Head Juvenile Diabetes Research Foundation (JDRF)

San Diego, CA (November 25, 2008) – Novocell, Inc., a stem cell engineering company, today announced that President and Chief Executive Officer Alan J. Lewis, Ph.D., will leave the company effective January 1, 2009 to […]
09.17.08

Novocell Awarded Landmark U.S. Patents for Innovative Stem Cell Technologies

San Diego, CA (September 17, 2008) – Novocell, Inc., a stem cell engineering company, today announced that the U.S. Patent and Trademark Office has issued two patents related to its stem cell encapsulation technology and […]
02.21.08

Stem Cell Therapy Controls Diabetes in Mice

The New York Times, Andrew Pollack, February 21, 2008: Scientists reported on Wednesday that they were able to control diabetes in mice by harnessing human embryonic stem cells. The work raised the prospect that the embryonic cells might […]
02.20.08

Stem Cells For Diabetes

Forbes, Robert Langreth, February 20, 2008: In progress toward a stem-cell treatment for diabetes, researchers at a small San Diego biotech company have devised a procedure for turning human embryonic stems cells into insulin-producing cells inside […]
02.20.08

Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice

San Diego, CA / February 20, 2008 – Novocell, Inc., a stem cell engineering company, today announced data demonstrating for the first time that human embryonic stem (hES) cells can be turned into pancreatic cells […]